Pancreatic cancer is still one of the most lethal cancers, in part, because it has spread or metastasized by the time it is diagnosed. One common site of metastasis for […]
Engineering CAR T cells to overcome immune suppression in pancreatic cancer
Chimeric antigen receptor (CAR) T cells, an immunotherapy that has been successful in treating blood cancers, has had limited efficacy in solid tumors including in pancreatic cancer. Greg Allen, MD, […]
Prepare and Thrive Through Pancreatic Cancer Treatment
Pancreatic cancer treatment is complex and often involves a combination of chemotherapy, surgery, and a demanding recovery. At the Hirshberg Foundation’s 20th Annual Symposium, Barbara Jagels, RN, MHA, CPHQ, Executive […]
What to Expect After Pancreatic Surgery
The Whipple procedure, also called pancreaticoduodenectomy, is a major operation used to treat pancreatic cancer. The surgery involves removing parts of the pancreas in an area of the digestive system […]
Dr. Mark Girgis Named Director of the UCLA Agi Hirshberg Center for Pancreatic Diseases
The Hirshberg Foundation for Pancreatic Cancer Research is pleased to welcome Dr. Mark D. Girgis as the new Director of the UCLA Agi Hirshberg Center for Pancreatic Diseases. As Director […]
First RAS inhibitor approved by the FDA
Today daraxonrasib, an oral RAS(ON) multi-selective inhibitor from Revolution Medicines, was approved by the FDA for use by patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) or for patients […]